PT - JOURNAL ARTICLE AU - Schroyens, Natalie AU - D’aes, Tine AU - Buck, Emmy De AU - Mikkelsen, Susan AU - Tiberghien, Pierre AU - van den Hurk, Katja AU - Erikstrup, Christian AU - Compernolle, Veerle AU - Remoortel, Hans Van AU - the SUPPLY consortium TI - Safety and protection of plasma donors: A scoping review and evidence (gap) map AID - 10.1101/2023.07.12.23292560 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.12.23292560 4099 - http://medrxiv.org/content/early/2023/07/14/2023.07.12.23292560.short 4100 - http://medrxiv.org/content/early/2023/07/14/2023.07.12.23292560.full AB - Background and objectives As part of a large-scale European project aiming to safely increase plasma collection in Europe, the current scoping review identifies the existing evidence (gaps) on adverse events (AEs) and other health effects in plasmapheresis donors, as well as factors that may be associated with such events/effects.Materials and methods We searched 6 databases and 3 registries. Study characteristics (publication type and language, study design, population, outcomes, associated factors, time of assessment, duration of follow-up, number and frequency of donations within the study period, convalescent plasma (y/n), study setting, and location) were charted in duplicate and in consultation with a content expert group. Results were synthesized narratively and in an interactive evidence gap map (EGM).Results Ninety-four research articles and 5 registrations focused on AEs (n = 38) and/or other health effects (n = 77) in plasmapheresis donors. Around 90% were observational studies (57 controlled; 33 uncontrolled), and most of them were performed in Europe (55%) or the USA (20%). Factors studied in association with donor health included donor characteristics (e.g., sex, age) (n = 27), cumulative number of donations (n = 21), donation frequency (n = 11), plasma collection device or program (n = 11), donor status (first-time versus repeat) (n = 10), donation volume per session (n = 8), time in donation program (n = 3), preventive measures (n = 2), or other (n = 9).Conclusion The current scoping review and EGM provide accessible tools for researchers and policy-makers to identify the available evidence and existing research gaps concerning plasmapheresis donation safety. Controlled, prospective studies with long-term donor follow-up are scarce. Furthermore, additional experimental studies comparing the health effects of different donation frequencies are required to inform a safe upper limit for donation frequency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the EU4Health Programme by the European Union (101056988) and the Foundation for Scientific Research of the Belgian Red Cross.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://osf.io/kbv6z. https://osf.io/kbv6z